Advertisement

Thromboxane A2 promotes soluble CD40 ligand release from human platelets

      Abstract

      Objective

      The plasma level of soluble CD40 ligand (sCD40L), which induces pro-inflammatory and pro-atherogenic responses, is known to be elevated in atherosclerotic patients. In this study, we investigated the mechanism of sCD40L release from human platelets, focusing on the involvement of thromboxane (TX) A2.

      Methods

      We measured sCD40L release and TXA2 production induced by ristocetin, an activator of GPIb/IX/V, from human platelets in vitro. Moreover, plasma sCD40L and TXA2 levels in the 10 patients with severe carotid artery stenosis who were not taking any anti-platelet medicines were measured and compared with those obtained from non-atherosclerotic controls.

      Results

      Ristocetin significantly promoted sCD40L release and TXA2 generation from platelets in vitro. Aspirin and SC-560, a cyclooxygenase-1 inhibitor, suppressed the ristocetin-induced sCD40L release from platelets in parallel with TXA2 production. Ozagrel, a TXA2 synthase inhibitor and PTXA2, a thromboxane receptor (TP) antagonist also suppressed sCD40L release. U46619, a TP agonist, reversed the suppressive effect of aspirin on sCD40L release. In vivo, plasma levels of sCD40L and TXA2 in the patients were significantly higher than those in controls. Elevated plasma levels of TXA2 and sCD40L in the patients were markedly diminished after 7 days of 100 mg aspirin administration.

      Conclusion

      These results strongly suggest that GPIb/IX/V activation induces sCD40L release via TXA2 from human platelets, and that sCD40L release via TXA2 generation from platelets in atherosclerotic patients are up-regulated.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Libby P.
        Inflammation in atherosclerosis.
        Nature. 2000; 420: 686-874
        • Henn V.
        • Slupsky J.R.
        • Gräfe M.
        • et al.
        CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells.
        Nature. 1998; 391: 591-594
        • Davì G.
        • Patrono C.
        Platelet activation and atherothrombosis.
        N Engl J Med. 2007; 357: 2482-2494
        • Furman M.I.
        • Krueger L.A.
        • Linden M.D.
        • et al.
        Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.
        J Am Coll Cardiol. 2004; 43: 2319-2325
        • Mach F.
        • Schönbeck U.
        • Sukhova G.K.
        • Atkinson E.
        • Libby P.
        Reduction of atherosclerosis in mice by inhibition of CD40 signaling.
        Nature. 1998; 394: 200-203
        • Heeschen C.
        • Dimmeler S.
        • Hamm C.W.
        • et al.
        Soluble CD40 ligand in acute coronary syndromes.
        N Engl J Med. 2003; 348: 1104-1111
        • Garlichs C.D.
        • Eskafi S.
        • Raaz D.
        • et al.
        Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets.
        Heart. 2001; 86: 649-655
        • Garlichs C.D.
        • Kozina S.
        • Fateh-Moghadam S.
        • et al.
        Upregulation of CD40–CD40 ligand (CD154) in patients with acute cerebral ischemia.
        Stroke. 2003; 34: 1412-1418
        • Santilli F.
        • Davì G.
        • Consoli A.
        • et al.
        Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus.
        J Am Coll Cardiol. 2006; 47: 391-397
        • Harding S.A.
        • Sommerfield A.J.
        • Sarma J.
        • et al.
        Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus.
        Atherosclerosis. 2004; 176: 321-325
        • Novo S.
        • Basili S.
        • Tantillo R.
        • et al.
        Soluble CD40L and cardiovascular risk in asymptomatic low-grade carotid stenosis.
        Stroke. 2005; 36: 673-675
        • Schönbeck U.
        • Varo N.
        • Libby P.
        • Buring J.
        • Ridker P.M.
        Soluble CD40L and cardiovascular risk in women.
        Circulation. 2001; 104: 2266-2268
        • de Lemos J.A.
        • Zirlik A.
        • Schönbeck U.
        • et al.
        Association between soluble CD40 ligand, atherosclerotic risk factors, and subclinical atherosclerosis: results from Dallas Heart Study.
        Arterioscler Thromb Vasc Biol. 2005; 25: 2192-2196
        • Nannizzi-Alaimo L.
        • Alves V.L.
        • Phillips D.R.
        Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
        Circulation. 2003; 107: 1123-1128
        • Berndt M.C.
        • Shen Y.
        • Dopheide S.M.
        • Gardiner E.E.
        • Andrews R.K.
        The vascular biology of the glycoprotein Ib–IX–V complex.
        Thromb Haemost. 2001; 86: 178-188
        • Dong J.F.
        • Berndt M.C.
        • Schade A.
        • et al.
        Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent interactions.
        Blood. 2001; 97: 162-168
        • Garcia A.
        • Quinton T.M.
        • Dorsam R.T.
        • Kunapuli S.P.
        Src family kinase-mediated and Erk-mediated thromboxane A2 generation are essential for VWF/GPIb-induced fibrinogen receptor activation in human platelets.
        Blood. 2005; 106: 3410-3414
        • Tamura N.
        • Yoshida M.
        • Ichikawa N.
        • et al.
        Shear-induced von Willebrand factor-mediated platelet surface translocation of the CD40 ligand.
        Thromb Res. 2003; 108: 311-315
        • Kato K.
        • Ito H.
        • Hasegawa K.
        • et al.
        Modulation of the stress-induced synthesis of hsp27 and alpha B-crystallin by cyclic AMP in C6 rat glioma cells.
        J Neurochem. 1996; 66: 946-950
        • Catella F.
        • Healy D.
        • Lawson J.A.
        • FitzGerald G.A.
        11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation.
        Proc Natl Acad Sci USA. 1986; 83: 5861-5865
        • Smith C.J.
        • Zhang Y.
        • Koboldt C.M.
        • et al.
        Pharmacological analysis of cyclooxygenase-1 in inflammation.
        Proc Natl Acad Sci USA. 1998; 95: 13313-13318
        • Naito J.
        • Komatsu H.
        • Ujiie A.
        • et al.
        Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets.
        Eur J Pharmacol. 1983; 91: 41-48
        • Nicolaou K.C.
        • Magolda R.L.
        • Smith J.B.
        • et al.
        Synthesis and biological properties of pinane-thromboxane A2, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation.
        Proc Natl Acad Sci USA. 1979; 76: 2566-2570
        • Bertelé V.
        • Di Minno G.
        • de Gaetano G.
        U-46619, a stable analogue of prostaglandin H2, induces retraction of human platelet-rich plasma clots.
        Thromb Res. 1980; 18: 543-545
        • Egan K.
        • FitzGerald G.A.
        Eicosanoids and the vascular endothelium.
        Handb Exp Pharmacol. 2006; 176: 189-211
        • Patrignani P.
        • Filabozzi P.
        • Patrono C.
        Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.
        J Clin Invest. 1982; 69: 1366-1372
        • Capone M.L.
        • Tacconelli S.
        • Sciulli M.G.
        • et al.
        Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
        Circulation. 2004; 109: 1468-1471
        • Nakahata N.
        Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology.
        Pharmacol Ther. 2008; 118: 18-35
        • Cuenda A.
        • Rouse J.
        • Doza Y.N.
        • et al.
        SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1.
        FEBS Lett. 1995; 364: 229-233
        • Alessi D.R.
        • Cuenda A.
        • Cohen P.
        • Dudley D.T.
        • Saltiel A.R.
        PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo.
        J Biol Chem. 1995; 270: 27489-27494
        • Bennett B.L.
        • Sasaki D.T.
        • Murray B.W.
        • et al.
        Anderson DW SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.
        Proc Natl Acad Sci USA. 2001; 98: 13681-13686
        • Liu J.
        • Pestina T.I.
        • Berndt M.C.
        • et al.
        The roles of ADP and TXA2 in botorocatin/VWF-induced aggregation of washed platelets.
        J Thromb Haemost. 2004; 2: 2213-2222
        • Pignatelli P.
        • Sanguigni V.
        • Lenti L.
        • et al.
        gp91phoz-dependent expression of platelet CD40 ligand.
        Circulation. 2004; 110: 1326-1329
        • Glagov S.
        • Weisenberg E.
        • Zarins C.K.
        • Stankunavicius R.
        • Kolettis G.J.
        Compensatory enlargement of human atherosclerotic coronary arteries.
        N Engl J Med. 1987; 316: 1371-1375
        • Korshunov V.A.
        • Schwartz S.M.
        • Berk B.C.
        Vascular remodeling: hemodynamic and biochemical mechanisms underlying Glagov's phenomenon.
        Arterioscler Thromb Vasc Biol. 2007; 27: 1722-1728
        • Malek A.M.
        • Alper S.L.
        • Izumo S.
        Hemodynamic shear stress and its role in atherosclerosis.
        JAMA. 1999; 282: 2035-2042
        • Kroll M.H.
        • Hellums J.D.
        • Mclntire L.V.
        • Schafer A.I.
        • Moake J.L.
        Platelets and shear stress.
        Blood. 1996; 88: 1525-1541
        • Holme P.A.
        • Orvim U.
        • Hamers M.J.
        • et al.
        Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis.
        Arterioscler Thromb Vasc Biol. 1997; 17: 646-653
        • Maalej N.
        • Holden J.E.
        • Folts J.D.
        Effects of shear stress on acute platelet thrombus formation in canine stenosed carotid arteries: an in vivo quantitative study.
        J Thromb Thrombolysis. 1998; 5: 231-238
        • Antithrombotic Trialists’ Collaboration
        Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients.
        BMJ. 2002; 324: 71-86
        • Nakamura T.
        • Jamieson G.A.
        • Okuma M.
        • Kambayashi J.
        • Tandon N.N.
        Platelet adhesion to native type I collagen fibrils. Role of GPVI in divalent cation-dependent and -independent adhesion and thromboxane A2 generation.
        J Biol Chem. 1998; 273: 4338-4344
        • Cipollone F.
        • Mezzetti A.
        • Porreca E.
        • et al.
        Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy.
        Circulation. 2002; 106: 399-402
        • Semb A.G.
        • van Wissen S.
        • Ueland T.
        • et al.
        Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy.
        J Am Coll Cardiol. 2003; 41: 275-279
        • Furberg C.D.
        • Adams Jr., H.P.
        • Applegate W.B.
        • et al.
        Effects of lovastatin on early carotid atherosclerosis and cardiovascular events, Aymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
        Circulation. 1994; 90: 1679-1687
        • Smilde T.J.
        • van Wissen S.
        • Wollersheim H.
        • et al.
        Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.
        Lancet. 2001; 357: 577-581
        • MacMahon S.
        • Sharpe N.
        • Gamble G.
        • et al.
        Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group.
        Circulation. 1998; 97: 1784-1790
        • Reid J.A.
        • Wolsley C.
        • Lau L.L.
        • et al.
        The effect of pravastatin on intima media thickness of the carotid artery in patients with normal cholesterol.
        Eur J Vasc Endovasc Surg. 2005; 30: 464-468
        • Amarenco P.
        • Bogousslavsky J.
        • Callahan 3rd., A.
        Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) investigators. High-dose atorvastatin after stroke or transient ischemic attack.
        N Engl J Med. 2006; 355: 549-559
        • Heart Protection Study Collaborative Group
        MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial.
        Lancet. 2002; 360: 7-22